Sorafenib
- TRADE NAME: Nexavar (Bayer)
- INDICATIONS: Advanced renal cell carcinoma
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 25–48 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bevacizumab, Carbamazepine, Clozapine, Conivaptan, Coumarins, CYP3A4 inducers, Darunavir, Delavirdine, Dexamethasone, Digoxin, Docetaxel, Doxorubicin, Efavirenz, Indinavir, Irinotecan, Neomycin, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort, Telithromycin, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
In combination with carboplatin and paclitaxel, Nexavar is contra-indicated in patients with squamous cell lung cancer.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/19/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric